Agree that the bio marker lab test results will be fast to turn around - but will be at PYC discretion as to when to release after due diligence and analysis and likely at the periodic SRC review juncture - i.e. safety outcomes met + bonus efficacy data observed
Either way today’s news update is a good one; and informs PYC’s progress which will be followed/scrutinised closely as I believe the industry has woken up following the US$1.4b deal for a like for like - with PYC likely to surprise US peers with additional patient efficacy outcomes (we hope)
Alnylam is a US $37.8 billion same space player and dare I say PYC ar US $0.45 B (A$700m) will be an interesting and very cheap (1.2% of their MC) strategic fit to acquire a complementary delivery + drug delivery - multi modality (precisely strike disease at will) platform with excellent in class efficacy data points.
PYC Price at posting:
$1.23 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)